[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-440473-105":59,"doc-detail-440473-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-retinal-thickness-fluctuations-with-ranibizumab-versus-aflibercept-in-neovascular-age-related-macular-degeneration-salt-12-month-results-from-a-multicentre-randomised-phase-iv-trial","Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT) - 12-month results from a multicentre, randomised, phase IV trial","","Background/aims compare fluctuations of central subfield retinal thickness (CSRT) in neovascular age-related macular degeneration patients treated with ranibizumab pro re nata versus aflibercept bimonthly therapy over 12 months in a prospective phase IV multicentre randomized study. Methods assessed CSRT stability between months 3 and 6 and correlated stability with functional outcomes at month 12 using spectral-domain optical coherence tomography. Results showed numerical regimen differences, with a predefined adjusted analysis favoring ranibizumab and no CSRT fluctuation–BCVA correlation at month 12. Adverse events were low.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-retinal-thickness-fluctuations-with-ranibizumab-versus-aflibercept-in-neovascular-age-related-macular-degeneration-salt-12-month-results-from-a-multicentre-randomised-phase-iv-trial/440473/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-retinal-thickness-fluctuations-with-ranibizumab-versus-aflibercept-in-neovascular-age-related-macular-degeneration-salt-12-month-results-from-a-multicentre-randomised-phase-iv-trial/440473.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the SALT 12-month study?","Question",{"text":112,"@type":113},"To compare how CSRT fluctuates between months 3 and 6 in patients with neovascular age-related macular degeneration treated with ranibizumab PRN versus aflibercept bimonthly, and to relate stability to functional outcomes at month 12.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ranibizumab and aflibercept administered?",{"text":117,"@type":113},"Ranibizumab was given according to best-corrected visual acuity and/or disease activity on spectral domain optical coherence tomography, whereas aflibercept used three initial monthly visits followed by bimonthly treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"Did retinal thickness fluctuation correlate with functional outcomes at month 12?",{"text":121,"@type":113},"The study found no correlation between the mean amplitude of CSRT fluctuation (months 3 to 6) and BCVA at month 12, despite earlier evidence that fluctuations can negatively affect outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},440473,1790760568,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Retina  \nClinical science  \nImpact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular agerelated macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial  \nHansjuergen T Agostini, 1 Rufino Silva  ,2 Frank G Holz,3 Michael Larsen,4 Lebriz Altay,5,6 Eric H Souied,7 Claudia Quiering,8 Uwe Rose,9  \nSandra Liakopoulos  , 10 on behalf of SALT study group  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/bjo-2024-326526](10.1136/bjo-2024-326526)) .  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nHansjuergen T Agostini;  \nhansjuergen.agostini@uniklinik[freiburg.de](freiburg.de)  \nPresented at the European Society of Retina Specialists (EURETINA) 2018 congress, Vienna, Austria.  \nReceived 20 September 2024 Accepted 1 July 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nTo cite: Agostini HT, Silva R, Holz FG, et al.  \nBr J Ophthalmol Epub ahead of print: [please include Day Month Year] . doi:10 . 1136/ bjo-2024-326526  \nABSTRACT  \nBackground/aims To compare fluctuations of central subfield retinal thickness (CSRT) in patients with neovascular age-related macular degeneration undergoing ranibizumab pro re nata versus aflibercept bimonthly treatment in a prospective 12 month, phase IV, randomised, multicentre study.  \nMethods Ranibizumab was administered according to best-corrected visual acuity (BCVA) and/or disease activity detected on spectral domain optical coherence tomography. Aflibercept was administered at three initial monthly visits followed by bimonthly treatment. CSRT stability was evaluated between months 3 and 6. CSRT stability was compared between groups and correlated with functional outcomes at month 12.  \nResults Fluctuations of CSRT showed a least-squares (LS) mean (95% CI) difference of −4.12 (−10 .22 to 1.98) µm between ranibizumab (25 . 16 (20 .09 to 30 . 24)µm) and aflibercept groups (29.28 (24.14 to 34.43) µm)(p=0 . 1850) . A predefined analysis of retinal stability, adjusted for baseline CSRT, showed a LS mean (95% CI) difference of −6.53 (−12 .47 to −0.58 µm) in favour of ranibizumab (23 . 53 (18 . 58 to 28 .49) µm) versus aflibercept (30 .06 (25 .04 to 35 .07) µm) (p=0 .0315) . Pearson’s correlation coefficient demonstrated no correlation between the mean amplitude of CSRT fluctuation between months 3 and 6, and BCVA at month 12 (r = −0 .0888) . Adverse event rates were low. Conclusions Numerical differences in retinal thickness fluctuations between months 3 and 6 were detected between treatment regimens. While the presence of fluctuations has previously been shown to have a negative impact on functional outcomes, our data showed no correlation between the mean amplitude of fluctuations and functional outcomes at month 12.  \nINTRODUCTION  \nAge-related macular degeneration (AMD) is a leading cause of severe and irreversible vision loss, affecting approximately 10%–13% of adults aged more than 65 years.1 2 Most cases of severe vision loss in AMD are observed inpatients with neovascular AMD (nAMD),3 4 eventhough this type accounts for only 10%–12%  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Retinal thickness fluctuations occur in patients treated with antivascular endothelial growth factor treatment and may have a negative impact on functional outcome.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ The amplitude of retinal thickness fluctuations between months 3 and 6 has no influence on functional outcome at month 12.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ The study adds to the understanding of retinal thickness fluctuations and their influence on functional outcomes.  \nof all AMD cases.5 6 Antivascular endothelial growth factor (anti-VEGF) agents are currently considered the stan","cbCaijFPMViTbUjh","https://ap.wps.com/l/cbCaijFPMViTbUjh","pdf",1164879,"English","# Abstract\n# Background/aims\n# Methods\n# Results\n# Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Methods\n## Study design\n## Patients\n## Outcomes and measurements","[{\"question\":\"What is the main goal of the SALT 12-month study?\",\"answer\":\"To compare how CSRT fluctuates between months 3 and 6 in patients with neovascular age-related macular degeneration treated with ranibizumab PRN versus aflibercept bimonthly, and to relate stability to functional outcomes at month 12.\"},{\"question\":\"How were ranibizumab and aflibercept administered?\",\"answer\":\"Ranibizumab was given according to best-corrected visual acuity and/or disease activity on spectral domain optical coherence tomography, whereas aflibercept used three initial monthly visits followed by bimonthly treatment.\"},{\"question\":\"Did retinal thickness fluctuation correlate with functional outcomes at month 12?\",\"answer\":\"The study found no correlation between the mean amplitude of CSRT fluctuation (months 3 to 6) and BCVA at month 12, despite earlier evidence that fluctuations can negatively affect outcomes.\"}]","Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT) - 12-month results from a multicentre, randomised, phase IV trial | PDF",1790692332]